Moderna and Immatics, a clinical-stage biopharmaceutical company developing T cell-redirecting cancer immunotherapies, entered into a strategic research and development collaboration to pioneer transformative therapies for cancer patients with high unmet medical need. Immatics will receive $120 million upfront plus research funding with the potential for additional milestone and royalty payments. The broad multi-platform collaboration will leverage the deep scientific expertise and core opera...